|
Indication & Dosage |
|
|
Oral |
HIV INFECTION COMBINED WITH OTHER ANTIRETROVIRALS |
Adult:
Initially, 300 mg bid for 1 day. May increase dose gradually by 100 mg bid over a period of 14 days to 600 mg bid. |
|
Oral |
HIV INFECTION COMBINED WITH OTHER ANTIRETROVIRALS |
Child:
>2 yr: 250 mg/m2 bid. Increase dose by 50 mg/m2 bid at 2-3 day intervals up to 400 mg/m2 bid. Max dose: 600 mg bid. |
|
Oral |
AS A PHARMACOKINETIC ENHANCER |
Adult:
To enhance the efficacy of other protease inhibitors: 100-200 mg once or twice daily. |
|
|
|
Administration |
Should be taken with food. |
|
|
Precautions |
Pregnancy; child; hepatic impairment; DM; haemophilia; pancreatitis. Monitor glucose, lipid, uric acid and blood counts. Ensure adequate hydration to reduce risk of nephrolithiasis. Discontinue treatment if patient develops haemolytic anaemia. |
|
|
Potentially Life-threatening
Adverse Drug Reactions |
Syncope, orthostatic hypotension; dry mouth, mouth ulcers, throat irritation, cough; dyspepsia, nausea, vomiting, diarrhoea, taste disturbance, seizures, anxiety, sweating, fever, asthenia, fatigue, headache, dizziness, paraesthesia, myalgia, skin rashes, pruritus, renal insufficiency, anaemia, raised WBC, raised prothrombin time, lipodystrophy, pancreatitis, electrolyte imbalance. |
|
|
Adverse Drug Reactions |
Hypersensitivity, anaphylaxis and Stevens-Johnson syndrome. |
|
|
Interactions |
Decreased plasma conc with phenobarbital, carbamazepine, dexamethasone, phenytoin, rifabutin and rifampicn. Increased plasma conc of certain drugs highly metabolized by CYP3A. May increase serum levels of sildenafil. |
|
|
|
|